ABOS Stock Summary and Trading Ideas (Acumen Pharmaceuticals | NASDAQ:ABOS)

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Acumen Pharmaceuticals trades on the NASDAQ stock market under the symbol ABOS.

As of December 12, 2025, ABOS stock price climbed to $2.14 with 270,100 million shares trading.

ABOS has a beta of 2.08, meaning it tends to be more sensitive to market movements. ABOS has a correlation of 0.22 to the broad based SPY ETF.

ABOS has a market cap of $129.63 million. This is considered a Micro Cap stock.

In the last 3 years, ABOS traded as high as $11.31 and as low as $.86.

The top ETF exchange traded funds that ABOS belongs to (by Net Assets): VTI, VXF, IWC, AVSC.

ABOS has underperformed the market in the last year with a return of +3.4%, while SPY returned +14.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ABOS shares. However, ABOS has outperformed the market in the last 3 month and 2 week periods, returning +62.1% and +13.8%, while SPY returned +4.0% and -0.2%, respectively. This indicates ABOS has been having a stronger performance recently.

ABOS support price is $1.84 and resistance is $2.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABOS shares will trade within this expected range on the day.